Aptinyx eval­u­ates fu­ture of the com­pa­ny fol­low­ing two failed tri­als, 60% lay­offs

This year has been tough for Aptinyx — two failed tri­als, a 60% cut in its work­force, and now the com­pa­ny has brought on a firm to help eval­u­ate the fu­ture of the com­pa­ny.

The press re­lease not­ed it’s work­ing with the firm Laden­burg Thal­mann as its fi­nan­cial ad­vi­sor to as­sist in ex­plor­ing and eval­u­at­ing “strate­gic al­ter­na­tives” — a process that a grow­ing group of strug­gling biotechs has em­barked on, some­times end­ing in a merg­er, as­set sale or wind-down.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters